15 active not recruiting, 12 recruiting, 12 terminated, 10 completed. 32 Phase 2, 14 Phase 1, 3 Early Phase 1, 3 Not applicable, 3 Phase 3.
Follow Stage IV Prostate Cancer AJCC v8: new trials by email Literature Review of Stage IV Prostate Cancer AJCC v8 trials Research Report on Stage IV Prostate Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration - Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 38 | 2025-08-27 | 2026-03-25 |
| Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 30 | 2025-08-25 | 2026-09-23 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation Patient Navigation, Genetic Counseling, Survey Administration - Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Not applicable | Recruiting | Thomas Jefferson University | 120 | 2025-01-01 | 2026-10-22 |
| Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review - Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 210 | 2024-07-09 | 2026-10-07 |
| Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network Training and Education, Educational Intervention, Discussion - Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8 | Recruiting | Thomas Jefferson University | 30 | 2024-06-03 | 2026-05-15 | |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Phase 3 | Active not recruiting | Mayo Clinic | 118 | 2024-04-04 | 2026-09-17 |
| Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Biospecimen Collection, Bone Scan, Brachytherapy - Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 90 | 2023-11-20 | 2023-11-13 |
| Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Abiraterone, Biospecimen Collection, Darolutamide - Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of California, Davis | 75 | 2023-11-09 | 2026-03-13 |
| Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab - Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Suspended | Emory University | 10 | 2023-06-07 | 2026-10-13 |
| Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration - Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 79 | 2022-11-21 | 2026-09-24 |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-09-26 | 2024-03-07 | |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Abemaciclib, Lutetium Lu 177-PSMA-617 - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Vadim S Koshkin | 30 | 2022-07-08 | 2026-07-24 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Atezolizumab, Cabozantinib S-malate - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Utah | 31 | 2022-03-29 | 2026-10-14 |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Decitabine and Cedazuridine, Enzalutamide - Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 1 | Terminated | Roswell Park Cancer Institute | 8 | 2022-01-26 | 2025-11-12 |
| Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection - Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Early Phase 1 | Recruiting | Mayo Clinic | 220 | 2021-12-29 | 2026-10-13 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones Questionnaire Administration, Tin Sn 117m Pentetate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2021-12-18 | 2025-10-03 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
Showing 20 of 56. Sign in to see all of them.
Prostatic Neoplasms (56) · Neoplasm Metastasis (8) · Ovarian Neoplasms (7) · Pancreatic Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinoma, Transitional Cell (4) · Colorectal Neoplasms (4) · Breast Neoplasms (3) · Lung Neoplasms (2) · Melanoma (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Anemia (1) · Blast Crisis (1)
Genital Diseases (56) · Genital Diseases, Male (56) · Genital Neoplasms, Male (56) · Male Urogenital Diseases (56) · Neoplasms by Site (56) · Prostatic Diseases (56) · Urogenital Diseases (56) · Neoplasms (55) · Urogenital Neoplasms (54) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9)
Magnetic Resonance Spectroscopy (12) · Specimen Handling (12) · enzalutamide (7) · Prednisone (6) · Radiation (6) · Abiraterone Acetate (5) · Biopsy (5) · deltacortene (5) · prednylidene (5) · Carboplatin (4) · Docetaxel (4) · Leuprolide (4) · Radiotherapy (4) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (4) · apalutamide (4)
M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (6) · Mayo Clinic (5) · City of Hope Medical Center (4) · University of Washington (4) · Jonsson Comprehensive Cancer Center (3) · Roswell Park Cancer Institute (3) · Thomas Jefferson University (3) · Alliance for Clinical Trials in Oncology (2) · OHSU Knight Cancer Institute (2) · Rahul Aggarwal (2) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Ryan Kohlbrenner, MD (1) · SWOG Cancer Research Network (1)
United States (55) · Chile (1) · Colombia (1) · Mexico (1) · Puerto Rico (1) · Switzerland (1)
Ana Aparicio (2) · Gurkamal Chatta (2) · Michael Schweizer (2) · Paul Corn (2) · A P Chen (1) · Alison M Schram (1) · Amar Kishan (1) · Amy Leader, DrPH, MPH (1) · Amy Leader, DrPh, MPH (1) · Arnold Chin (1) · Arpit Rao, MD (1) · Atish D Choudhury (1) · Atish D. Choudhury, MD, PhD (1) · Aung Naing (1) · Bagi Jana, MD (1)
PMID 33602654, PMID 34663638, PMID 35405009, PMID 35428207, PMID 35710085, PMID 36351402, PMID 38452310, PMID 38867077, PMID 39136560, PMID 39254446, PMID 39536751, PMID 39863139, PMID 40139261, PMID 40377420, PMID 40939237, PMID 41315064, PMID 41646361, PMID 41698328, PMID 42847673
P30CA033572 (3), P50CA097186 (2), U10CA180821 (2), P30CA042014 (1), P30CA093373 (1), P30CA168524 (1), R01MH115043 (1), U10CA180888 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186712 (1)